Literature DB >> 22431402

Synaptic underpinnings of altered hippocampal function in glutaminase-deficient mice during maturation.

Inna Gaisler-Salomon1, Yvonne Wang, Nao Chuhma, Hong Zhang, Yaela N Golumbic, Andra Mihali, Ottavio Arancio, Etienne Sibille, Stephen Rayport.   

Abstract

Glutaminase-deficient mice (GLS1 hets), with reduced glutamate recycling, have a focal reduction in hippocampal activity, mainly in CA1, and manifest behavioral and neurochemical phenotypes suggestive of schizophrenia resilience. To address the basis for the hippocampal hypoactivity, we examined synaptic plastic mechanisms and glutamate receptor expression. Although baseline synaptic strength was unaffected in Schaffer collateral inputs to CA1, we found that long-term potentiation was attenuated. In wild-type (WT) mice, GLS1 gene expression was highest in the hippocampus and cortex, where it was reduced by about 50% in GLS1 hets. In other brain regions with lower WT GLS1 gene expression, there were no genotypic reductions. In adult GLS1 hets, NMDA receptor NR1 subunit gene expression was reduced, but not AMPA receptor GluR1 subunit gene expression. In contrast, juvenile GLS1 hets showed no reductions in NR1 gene expression. In concert with this, adult GLS1 hets showed a deficit in hippocampal-dependent contextual fear conditioning, whereas juvenile GLS1 hets did not. These alterations in glutamatergic synaptic function may partly explain the hippocampal hypoactivity seen in the GLS1 hets. The maturity-onset reduction in NR1 gene expression and in contextual learning supports the premise that glutaminase inhibition in adulthood should prove therapeutic in schizophrenia.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22431402      PMCID: PMC3531559          DOI: 10.1002/hipo.22014

Source DB:  PubMed          Journal:  Hippocampus        ISSN: 1050-9631            Impact factor:   3.899


  69 in total

1.  Genome-wide atlas of gene expression in the adult mouse brain.

Authors:  Ed S Lein; Michael J Hawrylycz; Nancy Ao; Mikael Ayres; Amy Bensinger; Amy Bernard; Andrew F Boe; Mark S Boguski; Kevin S Brockway; Emi J Byrnes; Lin Chen; Li Chen; Tsuey-Ming Chen; Mei Chi Chin; Jimmy Chong; Brian E Crook; Aneta Czaplinska; Chinh N Dang; Suvro Datta; Nick R Dee; Aimee L Desaki; Tsega Desta; Ellen Diep; Tim A Dolbeare; Matthew J Donelan; Hong-Wei Dong; Jennifer G Dougherty; Ben J Duncan; Amanda J Ebbert; Gregor Eichele; Lili K Estin; Casey Faber; Benjamin A Facer; Rick Fields; Shanna R Fischer; Tim P Fliss; Cliff Frensley; Sabrina N Gates; Katie J Glattfelder; Kevin R Halverson; Matthew R Hart; John G Hohmann; Maureen P Howell; Darren P Jeung; Rebecca A Johnson; Patrick T Karr; Reena Kawal; Jolene M Kidney; Rachel H Knapik; Chihchau L Kuan; James H Lake; Annabel R Laramee; Kirk D Larsen; Christopher Lau; Tracy A Lemon; Agnes J Liang; Ying Liu; Lon T Luong; Jesse Michaels; Judith J Morgan; Rebecca J Morgan; Marty T Mortrud; Nerick F Mosqueda; Lydia L Ng; Randy Ng; Geralyn J Orta; Caroline C Overly; Tu H Pak; Sheana E Parry; Sayan D Pathak; Owen C Pearson; Ralph B Puchalski; Zackery L Riley; Hannah R Rockett; Stephen A Rowland; Joshua J Royall; Marcos J Ruiz; Nadia R Sarno; Katherine Schaffnit; Nadiya V Shapovalova; Taz Sivisay; Clifford R Slaughterbeck; Simon C Smith; Kimberly A Smith; Bryan I Smith; Andy J Sodt; Nick N Stewart; Kenda-Ruth Stumpf; Susan M Sunkin; Madhavi Sutram; Angelene Tam; Carey D Teemer; Christina Thaller; Carol L Thompson; Lee R Varnam; Axel Visel; Ray M Whitlock; Paul E Wohnoutka; Crissa K Wolkey; Victoria Y Wong; Matthew Wood; Murat B Yaylaoglu; Rob C Young; Brian L Youngstrom; Xu Feng Yuan; Bin Zhang; Theresa A Zwingman; Allan R Jones
Journal:  Nature       Date:  2006-12-06       Impact factor: 49.962

2.  Oxytocin facilitates female sexual maturation through a glia-to-neuron signaling pathway.

Authors:  Anne-Simone Parent; Grégory Rasier; Valérie Matagne; Alejandro Lomniczi; Marie-Christine Lebrethon; Arlette Gérard; Sergio R Ojeda; Jean-Pierre Bourguignon
Journal:  Endocrinology       Date:  2007-11-26       Impact factor: 4.736

3.  Paradoxical influence of hippocampal neurogenesis on working memory.

Authors:  Michael D Saxe; Gaël Malleret; Svetlana Vronskaya; Indira Mendez; A Denise Garcia; Michael V Sofroniew; Eric R Kandel; René Hen
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-05       Impact factor: 11.205

4.  BDNF-mediated neurotransmission relies upon a myosin VI motor complex.

Authors:  Hiroko Yano; Ipe Ninan; Hong Zhang; Teresa A Milner; Ottavio Arancio; Moses V Chao
Journal:  Nat Neurosci       Date:  2006-07-02       Impact factor: 24.884

5.  Assessment of NMDA receptor NR1 subunit hypofunction in mice as a model for schizophrenia.

Authors:  T B Halene; R S Ehrlichman; Y Liang; E P Christian; G J Jonak; T L Gur; J A Blendy; H C Dow; E S Brodkin; F Schneider; R C Gur; S J Siegel
Journal:  Genes Brain Behav       Date:  2009-05-08       Impact factor: 3.449

6.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats.

Authors:  B Moghaddam; B W Adams
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

Review 7.  A thalamo-hippocampal-ventral tegmental area loop may produce the positive feedback that underlies the psychotic break in schizophrenia.

Authors:  John E Lisman; Hyun Jae Pi; Yuchun Zhang; Nonna A Otmakhova
Journal:  Biol Psychiatry       Date:  2010-05-31       Impact factor: 13.382

Review 8.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence.

Authors:  P J Harrison; D R Weinberger
Journal:  Mol Psychiatry       Date:  2005-01       Impact factor: 15.992

9.  Implications for altered glutamate and GABA metabolism in the dorsolateral prefrontal cortex of aged schizophrenic patients.

Authors:  Martin R Gluck; Rohan G Thomas; Kenneth L Davis; Vahram Haroutunian
Journal:  Am J Psychiatry       Date:  2002-07       Impact factor: 18.112

10.  Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia -- Juntendo University Schizophrenia Projects (JUSP).

Authors:  Hitoshi Maeshima; Tohru Ohnuma; Yoshie Sakai; Nobuto Shibata; Hajime Baba; Hiroshi Ihara; Maiko Higashi; Taku Ohkubo; Eiko Nozawa; Sawako Abe; Aya Ichikawa; Yoshiyuki Nakano; Yushi Utsumi; Toshihito Suzuki; Heii Arai
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-06-22       Impact factor: 5.067

View more
  7 in total

1.  Dopamine neuron dependent behaviors mediated by glutamate cotransmission.

Authors:  Susana Mingote; Nao Chuhma; Abigail Kalmbach; Gretchen M Thomsen; Yvonne Wang; Andra Mihali; Caroline Sferrazza; Ilana Zucker-Scharff; Anna-Claire Siena; Martha G Welch; José Lizardi-Ortiz; David Sulzer; Holly Moore; Inna Gaisler-Salomon; Stephen Rayport
Journal:  Elife       Date:  2017-07-13       Impact factor: 8.140

Review 2.  Using human brain imaging studies as a guide toward animal models of schizophrenia.

Authors:  S S Bolkan; F Carvalho Poyraz; C Kellendonk
Journal:  Neuroscience       Date:  2015-05-30       Impact factor: 3.590

3.  Glutaminase activity in GLS1 Het mouse brain compared to putative pharmacological inhibition by ebselen using ex vivo MRS.

Authors:  Lauren Kosten; Golam M I Chowdhury; Susana Mingote; Steven Staelens; Douglas L Rothman; Kevin L Behar; Stephen Rayport
Journal:  Neurochem Int       Date:  2019-07-19       Impact factor: 3.921

Review 4.  Therapeutic strategies impacting cancer cell glutamine metabolism.

Authors:  Michael J Lukey; Kristin F Wilson; Richard A Cerione
Journal:  Future Med Chem       Date:  2013-09       Impact factor: 3.808

5.  Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network.

Authors:  Suleyman Gulsuner; Tom Walsh; Amanda C Watts; Ming K Lee; Anne M Thornton; Silvia Casadei; Caitlin Rippey; Hashem Shahin; Vishwajit L Nimgaonkar; Rodney C P Go; Robert M Savage; Neal R Swerdlow; Raquel E Gur; David L Braff; Mary-Claire King; Jon M McClellan
Journal:  Cell       Date:  2013-08-01       Impact factor: 41.582

Review 6.  Modeling resilience to schizophrenia in genetically modified mice: a novel approach to drug discovery.

Authors:  Andra Mihali; Shreya Subramani; Genevieve Kaunitz; Stephen Rayport; Inna Gaisler-Salomon
Journal:  Expert Rev Neurother       Date:  2012-07       Impact factor: 4.618

7.  Genetic Pharmacotherapy as an Early CNS Drug Development Strategy: Testing Glutaminase Inhibition for Schizophrenia Treatment in Adult Mice.

Authors:  Susana Mingote; Justine Masson; Celia Gellman; Gretchen M Thomsen; Chyuan-Sheng Lin; Robert J Merker; Inna Gaisler-Salomon; Yvonne Wang; Rachel Ernst; René Hen; Stephen Rayport
Journal:  Front Syst Neurosci       Date:  2016-01-08
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.